The reasoning seems flawless: matrix metalloproteinases (MMPs) are upregulated in tissue undergoing remodeling, as in cancer. A decrease in their activity negatively affects the invasive behavior of tumor cells in vitro and their ability to metastasize in experimental models. Inhibition of MMPs is therefore a logical target in cancer therapy and endogenous as well as synthetic inhibitors have been tested in human clinical trials. So far, the results have been most disappointing; however, the lessons learned from unsuccessful trials hold the promise for better design and selection of future inhibitors.
Go to Previous Page
Go to Next Page